Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)
Ultragenyx Pharmaceutical (RARE) posted quarterly Current Leases of $12.0 million for Q4 2025, up 20.0% year-over-year from $10.0 million in Q4 2024, and down 1.17% quarter-over-quarter from $12.1 million in Q3 2025.
Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Current Leases for 7 consecutive years, with $12.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Leases rose 20.0% year-over-year to $12.0 million; the TTM figure through Dec 2025 stood at $12.0 million (up 20.0% YoY), while the FY2025 annual figure was $12.0 million, up 20.0% from the prior year.
- Current Leases fell to $12.0 million in Q4 2025 per RARE's latest filing, from $12.1 million in the prior quarter.
- Across five years, Current Leases topped out at $12.8 million in Q1 2024 and bottomed at $9.4 million in Q1 2021.
- Historically, Current Leases has averaged $11.3 million across 5 years, with a median of $11.5 million in 2022.
- Annual changes were most pronounced in 2021 — Current Leases jumped 37.42% — and 2024, when it declined 20.6%.
- Ultragenyx Pharmaceutical's Current Leases stood at $11.1 million in 2021, then grew by 6.44% to $11.8 million in 2022, then increased by 6.93% to $12.6 million in 2023, then slipped by 20.6% to $10.0 million in 2024, then rose by 20.0% to $12.0 million in 2025.
- Business Quant data shows RARE's Current Leases at $12.0 million in Q4 2025, $12.1 million in Q3 2025, and $11.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.00 Mn |
| Sep 30, 2025 | 12.14 Mn |
| Jun 30, 2025 | 11.77 Mn |
| Mar 31, 2025 | 10.49 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 10.42 Mn |
| Jun 30, 2024 | 11.72 Mn |
| Mar 31, 2024 | 12.78 Mn |
| Dec 31, 2023 | 12.60 Mn |
| Sep 30, 2023 | 12.07 Mn |
| Jun 30, 2023 | 10.88 Mn |
| Mar 31, 2023 | 11.26 Mn |
| Dec 31, 2022 | 11.78 Mn |
| Sep 30, 2022 | 11.82 Mn |
| Jun 30, 2022 | 11.63 Mn |
| Mar 31, 2022 | 11.32 Mn |
| Dec 31, 2021 | 11.07 Mn |
| Sep 30, 2021 | 10.70 Mn |
| Jun 30, 2021 | 10.31 Mn |
| Mar 31, 2021 | 9.38 Mn |